東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Targeting IgV-like Domain Immune Che...

Prodeus, Aaron.

FindBook

Google Book

Amazon

博客來

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics./
作者:	Prodeus, Aaron.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	168 p.
附註:	Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
Contained By:	Dissertation Abstracts International79-12B(E).
標題:	Molecular biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10685283
ISBN:	9780438189409

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics.
Prodeus, Aaron.

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 168 p.

Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.

Thesis (Ph.D.)--University of Toronto (Canada), 2018.

The immune system is heavily regulated by negative checkpoint pathways; a network of cell signaling events governed by immune inhibitory ligand-receptor interactions. Physiologically, these negative checkpoint pathways are crucial for maintenance of self-tolerance in peripheral tissues. These pathways are often usurped by tumors as a mechanism to dampen anti-tumor immune responses. Clinically, the targeted blockade of PD-1:PD-L1 and CTLA-4:CD80/86 checkpoint ligand-receptor interactions using monoclonal antibodies has proved to be a viable means to provoke effective and durable anti-tumor responses. Conversely, agonists that stimulate these natural immunoinhibitory signaling pathways could potentially serve as immune-suppressants for treating patients with inflammatory and autoimmune disorders. The central theme of this thesis was to derive novel biotherapeutics that agonize or antagonize clinically-relevant checkpoint receptors. Specifically, the thesis focuses largely on targeting checkpoint receptors with short, single-stranded oligonucleotides, termed DNA aptamers, which bind molecular targets with affinity and specificity rivalling that of monoclonal antibodies. As a proof-of-principle, I first describe the derivation of DNA aptamers which bind to murine PD-1 and antagonize the PD-1:PD-L1 pathway to release anti-tumor immune responses and suppress the growth of a murine colon carcinoma tumor implant in-vivo. Second, I report the development of aptamers that bind to CD200R1 and agonize this inhibitory receptor. Strikingly, these anti-CD200R1 agonists were found to act as strong immunosuppressant's in mouse models of transplant rejection and allergy. Lastly, I described the engineering of a novel multimeric fusion protein, consisting of the extracellular IgV-like domain of the checkpoint ligand VISTA, fused to a short helical pentamerization domain derived from the cartilage oligomeric matrix protein. This soluble agonist readily inhibited T-cell activation in-vitro, and suppressed inflammation in models of transplant rejection and autoimmune hepatitis. Notably, this construct represents the first agonist targeting the as-of-yet discovered VISTA-receptor to stimulate immunoinhibitory signaling in-vivo.

ISBN: 9780438189409Subjects--Topical Terms:

517296
Molecular biology.

Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics.
LDR:03252nmm a2200313 4500 001 2202393
005 20190510112840.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438189409
035 $a (MiAaPQ)AAI10685283
035 $a (MiAaPQ)toronto:16931
035 $a AAI10685283
040 $a MiAaPQ $c MiAaPQ
100 1 $a Prodeus, Aaron. $3 3429145
245 1 0 $a Targeting IgV-like Domain Immune Checkpoint Receptors with Novel Nucleic Acid and Protein-based Therapeutics.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 168 p.
500 $a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 $a Adviser: Jean Gariepy.
502 $a Thesis (Ph.D.)--University of Toronto (Canada), 2018.
520 $a The immune system is heavily regulated by negative checkpoint pathways; a network of cell signaling events governed by immune inhibitory ligand-receptor interactions. Physiologically, these negative checkpoint pathways are crucial for maintenance of self-tolerance in peripheral tissues. These pathways are often usurped by tumors as a mechanism to dampen anti-tumor immune responses. Clinically, the targeted blockade of PD-1:PD-L1 and CTLA-4:CD80/86 checkpoint ligand-receptor interactions using monoclonal antibodies has proved to be a viable means to provoke effective and durable anti-tumor responses. Conversely, agonists that stimulate these natural immunoinhibitory signaling pathways could potentially serve as immune-suppressants for treating patients with inflammatory and autoimmune disorders. The central theme of this thesis was to derive novel biotherapeutics that agonize or antagonize clinically-relevant checkpoint receptors. Specifically, the thesis focuses largely on targeting checkpoint receptors with short, single-stranded oligonucleotides, termed DNA aptamers, which bind molecular targets with affinity and specificity rivalling that of monoclonal antibodies. As a proof-of-principle, I first describe the derivation of DNA aptamers which bind to murine PD-1 and antagonize the PD-1:PD-L1 pathway to release anti-tumor immune responses and suppress the growth of a murine colon carcinoma tumor implant in-vivo. Second, I report the development of aptamers that bind to CD200R1 and agonize this inhibitory receptor. Strikingly, these anti-CD200R1 agonists were found to act as strong immunosuppressant's in mouse models of transplant rejection and allergy. Lastly, I described the engineering of a novel multimeric fusion protein, consisting of the extracellular IgV-like domain of the checkpoint ligand VISTA, fused to a short helical pentamerization domain derived from the cartilage oligomeric matrix protein. This soluble agonist readily inhibited T-cell activation in-vitro, and suppressed inflammation in models of transplant rejection and autoimmune hepatitis. Notably, this construct represents the first agonist targeting the as-of-yet discovered VISTA-receptor to stimulate immunoinhibitory signaling in-vivo.
590 $a School code: 0779.
650 4 $a Molecular biology. $3 517296
650 4 $a Immunology. $3 611031
650 4 $a Medicine. $3 641104
690 $a 0307
690 $a 0982
690 $a 0564
710 2 $a University of Toronto (Canada). $b Medical Biophysics. $3 3181600
773 0 $t Dissertation Abstracts International $g 79-12B(E).
790 $a 0779
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10685283